Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.48 |
| ▸ | TSHR | P16473 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26239694 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842638 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL26309888 | 0.81 | PARP1 (0.40) | ERN1GAA | |
| SCHEMBL26309889 | 0.81 | PARP1 (0.40) | ERN1GAA | |
| SCHEMBL24842388 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842389 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842379 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842653 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842381 | 0.79 | ALDH1A1 (0.40) | ALDH1A1TSHRKDM4EKMT2AMEN1 | |
| SCHEMBL24842420 | 0.78 | ALDH1A1 (0.45) | ALDH1A1TSHRKDM4EKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | ALIGOS THERAPEUTICS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | ALIGOS THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002413-A1 | METHODS AND COMPOSITIONS FOR TARGETING PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885TSHR 2323/4885KDM4E 2935/4885 |
| US-11760761-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885TSHR 2323/4885KDM4E 2935/4885 |
| US-11760764-B2 | Methods and compositions for targeting PD-L1 | CD274, PDCD1LG2, PDCD1 | ALDH1A1 301/4885TSHR 2323/4885KDM4E 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.